Tufia C Haddad1, Jun He2, Ciara C O'Sullivan3, Beiyun Chen3, Donald Northfelt4, Amylou C Dueck4, Karla V Ballman5, Kathleen S Tenner3, Hannah Linden6, Joseph A Sparano7, Judith O Hopkins8, Chamath De Silva9, Edith A Perez10, Paul Haluska3, Matthew P Goetz3. 1. Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA. Haddad.Tufia@mayo.edu. 2. Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, USA. 3. Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA. 4. Mayo Clinic, Scottsdale, AZ, USA. 5. Weill Cornell Medical College, New York, NY, USA. 6. Seattle Cancer Care Alliance, Seattle, WA, USA. 7. Montefiore Medical Center, Bronx, NY, USA. 8. Southeast Clinical Oncology Research (SCOR) Consortium, Winston-Salem, NC, USA. 9. Kaiser Permanente-Rock Creek, Lafayette, CO, USA. 10. Mayo Clinic, Jacksonville, FL, USA.
Abstract
PURPOSE: To compare efficacy and safety of capecitabine and lapatinib with or without IMC-A12 (cituxumumab) in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab. PATIENTS AND METHODS: Following an initial safety run-in cohort, patients were randomized 1:2 to Arm A (capecitabine and lapatinib) or to Arm B (capecitabine, lapatinib, and cituxumumab). Given the frequency of non-hematologic grade ≥ 3 adverse events in those receiving the three-drug combination in the safety cohort, lapatinib and capecitabine doses were reduced in Arm B only. The primary objective was to determine if the addition of cituxumumab to capecitabine and lapatinib improved progression-free survival (PFS) compared with capecitabine and lapatinib. Secondary objectives included a comparison between arms of other clinical endpoints, safety, change in overall quality of life (QOL) and self-assessed fatigue, rash, diarrhea, and hand-foot syndrome. RESULTS: From July 2008 to March 2012, 68 patients (out of 142 planned) were enrolled and 63 were evaluable, including 8 for the safety run-in and 55 for the randomized cohort. Study enrollment was stopped early due to slow accrual. The addition of cituxumumab to capecitabine and lapatinib did not improve PFS (HR 0.93, 95% CI: 0.52-1.64). Furthermore, no difference in objective response rate or overall survival (OS) was observed. No difference between arms was observed in grade ≥ 3 adverse events, overall QOL change from baseline after 4 cycles of treatment. CONCLUSION: The addition of cituxumumab to lapatinib and capecitabine did not improve PFS or OS compared with lapatinib and capecitabine in patients with HER2-positive MBC. CLINICAL TRIAL REGISTRY: ClinicalTrials.gov Identifier: NCT00684983.
PURPOSE: To compare efficacy and safety of capecitabine and lapatinib with or without IMC-A12 (cituxumumab) in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab. PATIENTS AND METHODS: Following an initial safety run-in cohort, patients were randomized 1:2 to Arm A (capecitabine and lapatinib) or to Arm B (capecitabine, lapatinib, and cituxumumab). Given the frequency of non-hematologic grade ≥ 3 adverse events in those receiving the three-drug combination in the safety cohort, lapatinib and capecitabine doses were reduced in Arm B only. The primary objective was to determine if the addition of cituxumumab to capecitabine and lapatinib improved progression-free survival (PFS) compared with capecitabine and lapatinib. Secondary objectives included a comparison between arms of other clinical endpoints, safety, change in overall quality of life (QOL) and self-assessed fatigue, rash, diarrhea, and hand-foot syndrome. RESULTS: From July 2008 to March 2012, 68 patients (out of 142 planned) were enrolled and 63 were evaluable, including 8 for the safety run-in and 55 for the randomized cohort. Study enrollment was stopped early due to slow accrual. The addition of cituxumumab to capecitabine and lapatinib did not improve PFS (HR 0.93, 95% CI: 0.52-1.64). Furthermore, no difference in objective response rate or overall survival (OS) was observed. No difference between arms was observed in grade ≥ 3 adverse events, overall QOL change from baseline after 4 cycles of treatment. CONCLUSION: The addition of cituxumumab to lapatinib and capecitabine did not improve PFS or OS compared with lapatinib and capecitabine in patients with HER2-positive MBC. CLINICAL TRIAL REGISTRY: ClinicalTrials.gov Identifier: NCT00684983.
Entities:
Keywords:
HER2-positive; Insulin-like growth factor receptor; Metastatic breast cancer; Trastuzumab-resistance
Authors: Paul Haluska; Joan M Carboni; David A Loegering; Francis Y Lee; Mark Wittman; Mark G Saulnier; David B Frennesson; Kimberly R Kalli; Cheryl A Conover; Ricardo M Attar; Scott H Kaufmann; Marco Gottardis; Charles Erlichman Journal: Cancer Res Date: 2006-01-01 Impact factor: 12.701
Authors: Evan Y Yu; Hongli Li; Celestia S Higano; Neeraj Agarwal; Sumanta K Pal; Ajjai Alva; Elisabeth I Heath; Elaine T Lam; Shilpa Gupta; Michael B Lilly; Yoshio Inoue; Kim N Chi; Nicholas J Vogelzang; David I Quinn; Heather H Cheng; Stephen R Plymate; Maha Hussain; Catherine M Tangen; Ian M Thompson Journal: J Clin Oncol Date: 2015-04-06 Impact factor: 44.544
Authors: Paul Haluska; Michael Menefee; Elizabeth R Plimack; Jonathan Rosenberg; Donald Northfelt; Theresa LaVallee; Li Shi; Xiang-Qing Yu; Patricia Burke; Jiaqi Huang; Jaiqi Huang; Jaye Viner; Jennifer McDevitt; Patricia LoRusso Journal: Clin Cancer Res Date: 2014-07-14 Impact factor: 12.531
Authors: Lars M Wagner; Maryam Fouladi; Atif Ahmed; Mark D Krailo; Brenda Weigel; Steven G DuBois; L Austin Doyle; Helen Chen; Susan M Blaney Journal: Pediatr Blood Cancer Date: 2014-11-28 Impact factor: 3.167